All the Latest News


The latest from Iceni Pharmaceuticals

We are committed to providing the best information possible for those individuals and organisations interested in following our progress. This news section is reserved for press releases announcing significant events. Selected past releases are archived for your reference.


Iceni Pharmaceuticals launches as new company focusing on repurposing therapies in the field of oncology

25th May 2016, EDINBURGH, UK – Iceni Pharmaceuticals announces its launch as a new company, focusing on developing repurposed and reformulated cancer therapies. The company’s lead product Cilcane® (generic name cilengitide) …

Read more

Iceni Pharmaceuticals announces appointment of cilengitide inventor Prof. Dr. Horst Kessler to its Scientific Advisory Board

Edinburgh, UK. 2 April 2016. Iceni Pharmacuticals, an oncology drug development company announced today that Prof Dr Horst Kessler has joined its Scientific Advisory Board.
Read more

Iceni Pharmaceuticals parent company BigDNA Ltd announces completion of internal funding round

Edinburgh, UK. 1 March 2016. BigDNA Ltd, parent organisation of oncology drug development company Iceni Pharmaceuticals announced today that it has completed a £0.5M investment round from internal shareholders, including London-based Imprimatur Capital and the Scottish Investment Bank.
Read more